Alternative Bioequivalence Pathways (w/ Nanopharm)

About FLUIDDA

FLUIDDA has pioneered Functional Respiratory Imaging (FRI), a proprietary platform that fuses medical imaging, computational fluid dynamics, and artificial intelligence to quantify and visualize lung function in unprecedented detail. Its business model is dual-pronged: offering CRO services to accelerate and de-risk respiratory drug and device development for pharma/biotech, and providing clinical decision support tools (e.g., Broncholab®) for pulmonologists and radiologists. The company was acquired by Banook, a global clinical trial services leader, in late 2025, significantly enhancing its global reach and operational scale to drive adoption of its technology in both clinical research and personalized patient care.

Therapeutic Areas